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ARTIKEL PENELITIAN
ABSTRACT
Chronic Myeloid Leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia
chromosome. Imatinib mesylate is a selective inhibitor of this kinase. Data about clinical characteristic of patients with
chronic phase CML,  hematologic response to Imatinib, and gene mutation of BCR-Abl  is still rare in Indonesia. Design
and methods: This is a cross sectional study using retrospective medical record of patients with BCR-ABL positive
chronic phase CML at policlinic of Teratai Department of Internal Medicine Cipto Mangunkusumo National Hospital
during January-December 2009.  
Results : In a period of 1 year, we included 20 positive BCR-ABL patients with chronic phase CML. The median age  was
36 years (13-62 years). Males were slightly more frequent than females (12 vs 7) with ratio of 1.7:1. Seven patients
(36.8%) were from javanese ethnic. The features of patients were 15 (78.9%) chronic phase, 3 (15.8%) accelerated
phase and 1 (5.3%) blast crisis. 12 (63.2%) of patients had splenomegaly. Median of hemoglobin level were 9.9 g/dL (5-
14 g/dL), median of white-cell count were 73.000/uL (4.100-332.000/uL), and median of platelet count was 481.000/uL
(263.000-1.116.000/uL). Median of basophils was 1% (0%-10%) and median of peripheral blood blasts was 1% (0-22%).
A 3 months  Complete Hematologic Response (CHR) was achieved in 10/19 (52.6%) patients during the study, including
1 accelerated phase patient and 1 blast crisis patient. 18/19 (94.7%) had been treated by hydrea before treated by
imatinib, 1/19 (5.3%) never treated by any drugs for CML. 5/11(45.4%) are in low risk of Sokal score.
Conclusions: The median age of patients with chronic phase CML was 36 years with slightly more frequent in male.
Sixty three point two percent of patients had splenomegaly. Median of white-cell count was 73.000/uL (4.100-
332.000/uL) and median of peripheral blood blasts was 1% (0-22%). A 3 months Complete Hematologic Response
(CHR) was achieved in 52.6% patients.  
Keywords: Chronic phase CML, imatinib, hematologic response, mutation.
ABSTRAK
Leukemia Granulositik Kronik (LGK) disebabkan oleh gen BCR-Abl domain tyrosin kinase, produk dari kromosom
Philadelphia. Imatinib mesylate merupakan inhibitor selektif terhadap kinase tersebut. Di Indonesia, data mengenai
karakteristik pasien LGK fase kronik, respons hematologi terhadap imatinib, dan mutasi gen masih jarang ditemukan.
Metode dan desain: studi potong lintang ini menggunakan data rekam medik pasien yang didiagnosis sebagai LGK fase
kronik dengan BCR-ABL positif yang berobat ke Poliklinik Teratai Departemen Ilmu Penyakit Dalam Rumah Sakit Cipto
Mangunkusumo selama Januari – Desember 2009.
Hasil: dalam periode 1 tahun studi, peneliti mengikutsertakan 20 pasien LGK fase kronik yang memiliki BCR-ABL positif
dengan median umur 36 tahun (13-62 tahun). Pasien laki-laki lebih banyak dibandingkan dengan perempuan (12 vs 7)
dengan rasio 1,7: 1. Sebanyak tujuh pasien (36,8%) berasal dari suku Jawa. Dilaporkan juga karakteristik pasien adalah
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INTRODUCTION 
Chronic Myeloid Leukemia (CML) is a clonalmyeloproliferative disorder, characterized by
acquisition of the Philadelphia chromosome (Ph) in
leukemic stem cells and their progeny.1,2 The abnormal
Ph chromosome is the result of a reciprocal translocation
between chromosomes 9 and 22. The major consequence
of this translocation is the fusion of the ABL gene to the
BCR gene on chromosome 22.3 The BCR-ABL fusion gene
encodes a new protein of 190, 210 or 230 kd, depending
on the breakpoint on the BCR gene.4,5 All these BCR-ABL
fusion proteins have enhanced tyrosine kinase activity,
which is crucial for the development of the disease.6
Imatinib mesylate is highly effective in the treatment
and management of Ph-positive CML.7,8 This drug is
thought  to bind competitively to the adenosine
triphosphate (ATP)-docking site of tyrosine kinase
proteins, including ABL itself and the hybrid BCR/ABL
proteins.9
Point mutations, which impair imatinib binding by
interrupting critical contact point or by inducing a
conformation to which imatinib binding is reduced, were
identified as an important mechanism of  acquired
imatinib resistance.10
To date, more than 50 different point mutations
encoding for more than 40 different amino acid
substitutions in the BCR-ABL kinase domain have been
described in CML patients after relapse due to resistance
to imatinib.11 Some mutants, such as T315I and E255K,
are insensitive to imatinib at clinically achievable doses,
whereas others, such as M315T or Y253F, retain
immediate levels of sensitivity to imatinib.12 The
probability of finding a mutation increases with disease
stage.10 Nevertheless, it was reported that mutation may
be detected even before initiation of treatment with
imatinib.13
There is a large variation in the previously reported
frequency of mutations found in association with
imatinib resistance, ranging from 26 to 90% of the
patients.12,14
To the best of our knowledge, there have been no data
regarding the BCR-ABL KD mutation in Indonesian
patients, therefore this study was designed to
characterize pattern of mutation  who obtained a CHR
after imatinib mesylate treatment, in our division.
DESIGN AND METHODS 
Patients 
Between January-December 2009, 20 patients were
recruited from Teratai Policlinic, Cipto Mangunkusumo
General Hospital, from those results, 3 of them could not
be read because of technical problem, and 4 were
doubtful. We suceeded in sequencing of 13 patients,
9 were normal results and 4 mutated. From 4 mutated
patients, 1 patient with new paradigm and 3 were
clasically like the same as literatures (Table 1).
Subjects were considered as chronic phase (CP) if they
have less than 15% blasts, less than 30% plus
promyelocytes, less than 20% basophils in peripheral
blood (PB) or bone marrow (BM), and no extramedullary
infiltration of leukemic blasts other than liver and spleen. 
Also platelets should be greater than or equal to 100 x
109/L. Accelerated phase (AP) was defined by the
prescence of any of the following criteria in PB or BM : at
least blast 15-30%, more than 30% blasts plus
promyelocytes (with less than 30% blasts alone), more
than 20% basophils, or less than 100 x 109 platelets/L.
Blasts crisis (BC) was defined by the presence of more
than 30% bast in PB or BM, or extramedullary disease.
Complete Hematologic Response (CHR) : based on
ELN (European Leukemic Net) guidelines, which consist
of : WBC ‹ 10 x 109/L, basophils ‹ 5%, no : myelocytes,
promyelocytes, myeloblasts in the differential, platelets
count ‹ 450 x 109/L, spleen nonpalpable.15 Sokal’s score
defined as (11 x age + 35 x spleen + 89 x blasts + 0,4 x
platelet – 550)/1000. 
Sequencing Methods
Blood withdrawn from PB or BM, after that we isolated
mononuclear cells (MNC’s) with RBC lysis buffer. Total
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15 orang berada pada fase kronik (78,9%); 3 pasien berada pada fase akselerasi (15,8%) sementara 1 pasien mengalami krisis blast (5,3%); 12 pasien
(63,2%) ditemui adanya splenomegali; dan 5 dari 11 pasien dilaporkan memiliki skor Sokal yang rendah. Berdasarkan  hasil laboratorium didapati nilai
median hemoglobin 9,9 g/dL (5-14 g/dL); leukosit 73.000/uL (4.100-332.000/uL) dan nilai median trombosit 481.000/uL (263.000/uL-1.116.000/uL);
nilai median kadar basofil di darah perifer 1% (1-10%) dengan nilai median sel blast di perifer adalah 1% (0-22%). Selama studi, respons hematologik
komplet dalam 3 bulan dicapai oleh 10 dari 19 pasien (52,6%), termasuk di antaranya 1 pasien yang mengalami fase akselerasi dan 1 pasien yang lain
mengalami krisis blast. Sebanyak 18 pasien (94,7%) telah diobati dengan hydrea sebelum mendapat terapi Imatinib, sementara 1 pasien (5,3%) tidak
pernah mendapatkan pengobatan apapun sebelumnya.
Kesimpulan: didapati nilai median usia pasien LGK fase kronik adalah 36 tahun, sebagian besar adalah laki-laki. Sebanyak enam puluh tiga persen
pasien memiliki splenomegali. Dilaporkan juga nilai median leukosit adalah 73.000/uL (4.100-332.000/uL) dengan nilai median sel blast di darah
perifer sebanyak 1% (0-22%). Respons hematologik komplet dalam 3 bulan dicapai oleh 52,6% pasien.
Kata kunci: LGK fase kronik, imatinib, respons hematologik, mutasi.
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amount of RNA were extracted with Trizol® reagent
(Invitrogen), after that we synthesized first strand cDNA
using random hexamer primer – M-MLV reverse
transcriptase (Invitrogen), and 100 ng of RNA template.
For nested PCR, we used KOD Hot Start DNA polymerase
(Toyobo).
For first PCR we’re using primer B2A and A10R1;
cDna template; PCR product 1,754 bp. For second we’re
using A4F and A10R2; PCR product template ; PCR
product 905 bp.
RESULTS 
In this study, we performed clinical characteristic,
hematologic evaluation, and mutation screening of 20
Indonesian CML patients. Characteristic of patients are
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Table 1: Patients characteristics at onset of Imatinib (IM) therapy*
Characteristic  (N=21) No. %
1. Age, years :
- Median 36,38
- Range 13-62
2. Sex :
- Male 12 63,2
- Female 7 36,8
3. Ethnics :
- Javanese 7 36,8
- Sundanese 2 10,5
- Balinese 0 0
- Batak 2 10,5
- Chinese 1 5,3
- Others 7 36,8
4. Sokal risk group :
- Low 5 26,3
- Intermediate 4 21,1
- High 10 52,6
5. Splenomegaly :
- Spleen size ≥ 10 cm below 7 36,8
the costal margin
6. Hemoglobin : (g/dl)
- Median 9,9
- Range 5-14
7. Leukocyte  : (x109/L)
- Median 73
- Range 4,1-332
8. Peripheral-blood blasts : (%)
- Median 1
- Range 0-22
9. Peripheral-blood basophils : (%)
- Median 1
- Range 0-13
10. Trombocyte : (x109/L)
- Median 481
- Range 263-1116
*Source : Dharmais National Cancer Centre and Ciptomangunkusumo
National General Hospital
Table 2: Patient responses (N=19)
Response No. %
CHR :
- No 7 36,8
*Progression
-Yes 10 52,6
*Loss of CHR
*Progression 
Abbreviations : CHR :  Complete Hematologic Response. Progression :
accelerated (AP) or blastic crisis (BC).
Figure 1: Deletion of exon 7 & 8 resulted in frame shift and premature
termination (ABS)
Figure: 2 M351T mutations (HY & TK)
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shown in table 1.  We carried out direct sequencing for all
patients to detect mutation in BCR-ABL KD.
A baseline PCR test is needed to confirm the type
of BCR-Abl transcripts that are expressed to enable
proper interpretation of subsequent results. There is
no proven prognostic value for the actual baseline
BCR-Abl level.
Twice monthly blood count monitoring for the first few
months is valuable to document achievement of CHR,
which is nearly always achieved in the first 3 months. RQ-
PCR can be done monthly for the first 3 months, but its
value at this stage is unproven. The result at 3 months
provides an indication of the probability that MMR will
eventually be achieved but is not yet very predictive of
progression-free survival (PFS). 
Figure 1 shows that from sequece reference, there was
deletion at exon no. 7 and 8, no evidence of imatinib
influencing.
DISCUSSION
We have enrolled 20 CML BCR-ABL (+) patients,
whom evaluated for CHR and gene mutations. From those
results, 3 of them could not be read because of technical
problem (purifications were not good), 4 were doubtful
(forward and reverse direction were not the same). We
suceeded in sequencing of 13 patients, 9 were normal, 4
mutated (ABS, HY, TK and MSS). From 4 mutated patients,
3 of them reached CHR (ABS,MSS and TK). One patient
(HY) didn’t. Although 3 patients succeded in  CHR , but
the time to reach it were not the same (ABS : 3 mo’s, MSS
and TK : 6 mo’s). We conclude that patients with
mutations still have good clinical responses. ❖
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Figure 3: Y253H (P-loop) mutation. Patient MSS
Table 4 : Clinical responses patients with mutation
No. Initial Phase Sokal’s score Duration of Illness Response Mutation
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